Human Monoclonal Antibodies Targeting HCV E2 Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are inadequate, with limited effectiveness and safety issues, and existing antibodies may not adequately cover all epitopes of the E2 protein, leading to insufficient viral neutralization.
Innovation Solution
Development of human monoclonal antibodies (RYB1, RYB2, and RYB3) targeting new, previously undescribed epitopes on the HCV E2 protein, specifically designed to bind to epitopes Ep1, Ep2, and Ep3, which include amino acid sequences not previously recognized, to enhance viral neutralization and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing monoclonal antibodies are used to treat HCV infection, then some neutralization effect is achieved, but the coverage of all epitopes of the E2 protein is insufficient, leading to limited viral neutralization effectiveness
Solution Approach 1:
The invention divides the E2 protein into multiple distinct epitope regions (Ep1, Ep2, Ep3, etc.) and develops separate monoclonal antibodies for each region. This segmentation allows comprehensive coverage of different epitopes, preventing the virus from escaping through single-point mutations while enhancing overall neutralization effectiveness.
Solution Approach 2:
The invention combines multiple monoclonal antibodies (RYB1, RYB2, RYB3, etc.) that target different epitopes into a cocktail formulation. This merging creates a synergistic effect where the antibodies work together to achieve broader and more potent viral neutralization compared to individual antibodies alone.
2Productivity
If current treatment methods are used, then some therapeutic effect is achieved, but safety issues and limited effectiveness persist
Solution Approach 1:
The invention changes the therapeutic parameter from conventional antiviral drugs to fully human monoclonal antibodies. This parameter change provides a safer alternative with reduced side effects while improving treatment effectiveness, as the antibodies are specifically designed to target HCV epitopes with high precision and minimal off-target effects.
3Quantity of substance
If monoclonal antibodies target known epitopes, then binding is achieved, but neutralization capability is insufficient due to previously undescribed epitopes remaining untargeted
Solution Approach 1:
The invention performs preliminary identification and characterization of new epitope sequences on the E2 protein before developing antibodies. By mapping and describing previously undescribed epitopes (Ep1, Ep2, Ep3, etc.) in advance, the research enables the design of antibodies that specifically target these regions, enhancing neutralization capability beyond what was previously achievable with known epitopes only.
Data Source
AI summary
The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies—RYB1, RYB2 and RYB3—and of a composition based thereon for the prevention and treatment of hepatitis C. Said antibodies are produced by cultivation using hybrid BIONA-RYB1, BIONA-RYB2 and BIONA-RYB3. The effectiveness of the antibodies is due to said antibodies binding epitopes, namely Ep1, Ep2 and Ep3 of E2 protein of the hepatitis C viral envelope, respectively. The present invention has demonstrated a neutralizing activity of the antibodies in a model system of infection of human cells in a culture. It has been shown that use of the claimed group of inventions provides for more reliable antibody binding of the hepatitis C virus.